ACOR RSI Chart
Last 7 days
34.6%
Last 30 days
-94.7%
Last 90 days
-95.6%
Trailing 12 Months
-92.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 118.3M | 116.9M | 111.1M | 117.6M |
2022 | 122.7M | 122.0M | 124.1M | 118.6M |
2021 | 153.7M | 151.9M | 130.3M | 129.1M |
2020 | 176.4M | 159.9M | 165.3M | 153.0M |
2019 | 409.4M | 306.2M | 211.1M | 192.4M |
2018 | 575.1M | 588.9M | 590.7M | 471.4M |
2017 | 523.1M | 535.1M | 540.5M | 588.3M |
2016 | 508.7M | 522.5M | 509.9M | 519.6M |
2015 | 420.8M | 437.4M | 479.6M | 492.7M |
2014 | 345.1M | 355.2M | 376.2M | 401.5M |
2013 | 306.4M | 317.8M | 325.3M | 336.4M |
2012 | 302.2M | 312.6M | 297.0M | 305.8M |
2011 | 235.1M | 256.9M | 286.3M | 292.2M |
2010 | 57.3M | 86.0M | 135.2M | 191.1M |
2009 | 0 | 53.8M | 54.2M | 54.7M |
2008 | 0 | 0 | 0 | 53.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 17, 2023 | cohen ron | bought | 6,500 | 0.65 | 10,000 | president and ceo |
Mar 16, 2023 | cohen ron | bought | 6,093 | 0.6 | 10,156 | president and ceo |
Sep 03, 2022 | clem kerry m | sold (taxes) | -601 | 0.398 | -1,511 | chief commercial officer |
Sep 03, 2022 | sabella lauren m | sold (taxes) | -601 | 0.398 | -1,511 | chief operating officer |
Mar 17, 2022 | cohen ron | sold | -3,894 | 1.7014 | -2,289 | president and ceo |
Sep 03, 2021 | morales robert | sold (taxes) | -1,962 | 4.38 | -448 | interim pao & pfo |
Sep 03, 2021 | sabella lauren m | sold (taxes) | -6,618 | 4.38 | -1,511 | chief commercial officer |
Sep 03, 2021 | cohen ron | sold (taxes) | -17,257 | 4.38 | -3,940 | president and ceo |
Mar 03, 2021 | blank burkhard | acquired | - | - | 11,125 | cmo and head of r&d |
Mar 03, 2021 | sabella lauren m | acquired | - | - | 11,125 | chief commercial officer |
Which funds bought or sold ACOR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.69 | 2,190 | 163,093 | -% |
Feb 14, 2024 | Davidson Kempner Capital Management LP | unchanged | - | 51,285 | 801,257 | 0.02% |
Feb 14, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
Feb 14, 2024 | Saltoro Capital, LP | unchanged | - | -146,250 | 731,250 | 1.95% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 754 | 754 | -% |
Feb 14, 2024 | DEUTSCHE BANK AG\ | sold off | -100 | -25,483 | - | -% |
Feb 13, 2024 | MORGAN STANLEY | unchanged | - | 116 | 17,745 | -% |
Feb 13, 2024 | ACADIAN ASSET MANAGEMENT LLC | unchanged | - | - | 489,000 | -% |
Unveiling Acorda Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Acorda Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 359.2B | 85.6B | 9.34 | 4.19 | ||||
MRK | 323.0B | 61.4B | 140.05 | 5.26 | ||||
AMGN | 166.9B | 29.5B | 44.36 | 5.65 | ||||
PFE | 157.1B | 46.5B | -113.14 | 3.37 | ||||
GILD | 80.7B | 27.1B | 14.25 | 2.98 | ||||
TEVA | 15.6B | 15.8B | -27.18 | 0.99 | ||||
MID-CAP | ||||||||
PRGO | 4.4B | 4.7B | -349.99 | 0.95 | ||||
ALKS | 4.1B | 1.7B | 9.38 | 2.36 | ||||
BHC | 2.9B | 9.0B | -6.3 | 0.32 | ||||
AMPH | 2.0B | 644.4M | 14.84 | 3.17 | ||||
SMALL-CAP | ||||||||
TLRY | 1.6B | 743.2M | -4.6 | 2.18 | ||||
TXMD | 22.0M | 1.3M | -2.14 | 16.92 | ||||
ACRX | 17.1M | - | -0.93 | 0.22 | ||||
AGRX | 2.5M | 19.6M | -0.17 | 0.13 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Acorda Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 37.1% | 37,985,000 | 27,715,000 | 29,675,000 | 22,258,000 | 31,470,000 | 33,511,000 | 31,051,000 | 22,534,000 | 36,967,500 | 31,456,000 | 31,785,000 | 28,862,000 | 38,160,000 | 53,090,000 | 33,618,000 | 28,099,000 | 50,496,000 | 47,722,000 | 50,053,000 | 44,137,000 | 69,152,000 |
Costs and Expenses | 843.7% | 285,310,000 | 30,234,000 | 33,307,000 | 33,734,000 | 31,203,000 | 38,500,000 | 44,966,000 | 39,237,000 | 48,526,500 | 54,465,000 | 47,474,000 | 57,643,000 | 116,554,500 | 37,053,000 | 43,168,000 | 34,268,000 | 36,010,500 | 307,072,000 | 73,442,000 | 87,516,000 | 118,452,500 |
S&GA Expenses | -4.1% | 22,206,500 | 23,152,000 | 21,825,000 | 22,514,000 | 26,254,000 | 22,997,000 | 30,067,000 | 26,938,000 | 28,440,000 | 29,623,000 | 32,368,000 | 33,968,000 | 32,876,500 | 39,935,000 | 38,656,000 | 41,108,000 | 41,224,000 | 48,702,000 | 50,195,000 | 52,725,000 | 36,819,000 |
R&D Expenses | -16.4% | 1,009,000 | 1,207,000 | 1,550,000 | 1,386,000 | 1,202,000 | 1,383,000 | 1,525,000 | 1,694,000 | 1,366,000 | 1,931,000 | 2,374,000 | 4,749,000 | 4,323,000 | 5,729,000 | 5,255,000 | 7,705,000 | 9,023,000 | 16,073,000 | 18,959,000 | 16,028,000 | 27,058,000 |
EBITDA Margin | -597.2% | -1.98 | 0.40 | 0.35 | 0.28 | 0.23 | -0.10 | -0.25 | -0.27 | -0.35 | -0.84 | -0.45 | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 2.8% | 8,205,000 | 7,984,000 | 7,773,000 | 7,571,000 | 7,699,000 | 7,465,000 | 7,474,000 | 7,562,000 | 7,338,000 | 7,167,000 | 7,705,000 | 7,825,000 | 7,764,000 | 7,760,000 | 7,484,000 | 7,566,000 | 5,570,000 | 4,500,000 | 5,378,000 | 6,424,000 | 5,271,000 |
Income Taxes | -3362.5% | -38,088,000 | -1,100,000 | -2,000,000 | -2,000,000 | 2,419,000 | 1,400,000 | 26,600,000 | 300,000 | 1,680,000 | -3,100,000 | -500,000 | -3,200,000 | -3,092,000 | 1,465,000 | 571,000 | -6,998,000 | -791,500 | 20,000 | 214,000 | -715,000 | -63,081,500 |
Earnings Before Taxes | -2473.4% | -255,870,000 | -9,943,000 | -11,346,000 | -18,862,000 | 21,574,000 | -12,438,000 | -20,119,000 | -24,264,000 | -18,899,500 | -30,176,000 | -23,395,000 | -36,603,000 | -86,159,000 | 8,812,000 | -16,850,000 | -13,470,000 | 64,862,000 | -263,518,000 | -27,272,000 | -48,320,000 | -53,465,500 |
EBT Margin | -1405.2% | -2.52 | -0.17 | -0.18 | -0.25 | -0.30 | -0.61 | -0.77 | -0.79 | -0.85 | -1.35 | -0.90 | - | - | - | - | - | - | - | - | - | - |
Net Income | -2350.1% | -217,761,000 | -8,888,000 | -9,381,000 | -16,824,000 | 19,142,000 | -13,854,000 | -46,682,000 | -24,522,000 | -20,567,500 | -27,071,000 | -22,864,000 | -33,451,000 | -83,048,000 | 7,347,000 | -17,421,000 | -6,472,000 | 65,660,000 | -263,535,000 | -27,486,000 | -47,605,000 | 9,595,000 |
Net Income Margin | -1397.4% | -2.15 | -0.14 | -0.18 | -0.49 | -0.56 | -0.85 | -0.97 | -0.77 | -0.81 | -1.28 | -0.87 | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -140.2% | -3,062,000 | 7,608,000 | -11,556,000 | -7,018,000 | 9,066,000 | -1,866,000 | -14,584,000 | -13,676,000 | 3,239,000 | -9,012,000 | -8,824,000 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -70.4% | 109 | 366 | 365 | 375 | 396 | 393 | 406 | 424 | 455 | 466 | 491 | 584 | 633 | 710 | 728 | 754 | 800 | 880 | 1,197 | 1,234 | 1,300 |
Current Assets | 1.4% | 75.00 | 74.00 | 65.00 | 68.00 | 82.00 | 72.00 | 77.00 | 80.00 | 102 | 97.00 | 113 | 190 | 221 | 152 | 158 | 168 | 201 | 314 | 358 | 418 | 528 |
Cash Equivalents | -7.7% | 30.00 | 32.00 | 25.00 | 30.00 | 38.00 | 21.00 | 23.00 | 32.00 | 46.00 | 36.00 | 46.00 | 117 | 71.00 | 58.00 | 41.00 | 32.00 | 62.00 | 120 | 148 | 197 | 294 |
Inventory | -10.0% | 16.00 | 18.00 | 15.00 | 13.00 | 13.00 | 15.00 | 15.00 | 15.00 | 19.00 | 21.00 | 25.00 | 27.00 | 29.00 | 30.00 | 33.00 | 26.00 | 25.00 | 27.00 | 28.00 | 31.00 | 29.00 |
Net PPE | -5.9% | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 6.00 | 7.00 | 139 | 142 | 143 | 143 | 131 | 113 | 83.00 | 61.00 |
Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 281 | 280 | 282 |
Current Liabilities | 392.0% | 228 | 46.00 | 30.00 | 35.00 | 38.00 | 42.00 | 41.00 | 46.00 | 54.00 | 68.00 | 68.00 | 133 | 137 | 139 | 138 | 71.00 | 86.00 | 92.00 | 94.00 | 97.00 | 140 |
Long Term Debt | -100.0% | - | 181 | 176 | 171 | 167 | 163 | 159 | 155 | 151 | 147 | 144 | 141 | 138 | 135 | 132 | 195 | 193 | 326 | 324 | 321 | 319 |
LT Debt, Non Current | -100.0% | - | 181 | 176 | 171 | 167 | 163 | 159 | 155 | 151 | 147 | 144 | 141 | 138 | 135 | 132 | 195 | 193 | 326 | 324 | 321 | 319 |
Shareholder's Equity | 167.9% | 158 | 59.00 | 68.00 | 77.00 | 94.00 | 76.00 | 88.00 | 128 | 151 | 164 | 190 | 206 | 238 | 314 | 291 | 307 | 311 | 281 | 545 | 567 | 612 |
Retained Earnings | -22.4% | -1,189 | -971 | -962 | -953 | -936 | -955 | -941 | -894 | -870 | -849 | -822 | -799 | -766 | -683 | -690 | -673 | -666 | -732 | -468 | -441 | -393 |
Additional Paid-In Capital | 0.0% | 1,030 | 1,030 | 1,030 | 1,030 | 1,030 | 1,030 | 1,029 | 1,024 | 1,023 | 1,016 | 1,016 | 1,008 | 1,008 | 1,000 | 983 | 981 | 979 | 1,015 | 1,012 | 1,009 | 1,005 |
Shares Outstanding | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 16.00 | - | - | - | 11.00 | - | - | - | 52.00 | - | - | - | 35.00 | - | - | - | 363 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -139.7% | -3,018 | 7,608 | -11,556 | -7,018 | 9,066 | -1,839 | -14,514 | -13,637 | 3,240 | -9,012 | -8,688 | -26,888 | 1,448 | -2,905 | -20,770 | -38,779 | -11,429 | -24,351 | -14,891 | -77,496 | -12,338 |
Share Based Compensation | -2.1% | 138 | 141 | 128 | 71.00 | 173 | 364 | 471 | 485 | 480 | 854 | 954 | 707 | 1,588 | 2,480 | 2,056 | 1,976 | 2,756 | 3,293 | 4,534 | 3,667 | 5,006 |
Cashflow From Investing | -Infinity% | -44.00 | - | - | - | 123 | -150 | -70.00 | -39.00 | -1.00 | - | -136 | 73,915 | 5,019 | 20,148 | 23,150 | 11,043 | 55,998 | -3,276 | -35,106 | -18,121 | -14,829 |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | - | - | -69,000 | -655 | - | -90.00 | - | -1,578 | -59,869 | - | -39.00 | -642 | 62.00 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00 | 52.00 | 157 |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues: | ||
Total net revenues | $ 117,633 | $ 118,566 |
Costs and expenses: | ||
Cost of sales | 15,283 | 30,332 |
Research and development | 5,152 | 5,804 |
Selling, general and administrative | 89,698 | 106,256 |
Intangible asset impairment | 251,322 | |
Amortization of intangible assets | 30,764 | 30,764 |
Changes in fair value of derivative liability | (37) | |
Changes in fair value of acquired contingent consideration | (9,634) | (6,659) |
Other operating income | (12,554) | |
Total operating expenses | 382,585 | 153,906 |
Operating loss | (264,952) | (35,340) |
Other income (expense), net: | ||
Interest and amortization of debt discount expense | (31,533) | (30,200) |
Interest income | 530 | 1,909 |
Realized Gain (Loss) on FX Currency | (288) | (8) |
Gain on extinguishment of debt | 27,142 | |
Gain on disposal of property and equipment | 171 | |
Other income (expense) | 51 | 1,250 |
Total other income (expense), net | (31,069) | 93 |
Loss before taxes | (296,021) | (35,247) |
Benefit from (Provision for) income taxes | 43,167 | (30,669) |
Net loss | $ (252,854) | $ (65,916) |
Net loss per share—basic | $ (203.57) | $ (65.23) |
Net loss per share—diluted | $ (203.57) | $ (65.23) |
Weighted average common shares outstanding used in computing net loss per share—basic | 1,242 | 1,011 |
Weighted average common shares outstanding used in computing net loss per share—diluted | 1,242 | 1,011 |
Net Product Revenues | ||
Revenues: | ||
Total net revenues | $ 102,421 | $ 103,845 |
Royalty Revenues | ||
Revenues: | ||
Total net revenues | 15,113 | 14,221 |
License Revenue | ||
Revenues: | ||
Total net revenues | $ 99 | $ 500 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 29,979 | $ 37,536 |
Restricted cash | 381 | 6,884 |
Trade accounts receivable, net of allowances of $962 and $842, as of December 31, 2023 and 2022, respectively | 17,298 | 13,866 |
Prepaid expenses | 5,211 | 4,312 |
Inventory, net | 16,155 | 12,752 |
Other current assets | 5,770 | 6,765 |
Total current assets | 74,794 | 82,115 |
Property and equipment, net of accumulated depreciation | 2,079 | 2,603 |
Intangible assets, net of accumulated amortization and impairment | 22,987 | 305,087 |
Right of use asset, net of accumulated amortization | 4,221 | 5,287 |
Restricted cash | 255 | 255 |
Other assets | 4,189 | 248 |
Total assets | 108,525 | 395,595 |
Current liabilities: | ||
Accounts payable | 13,373 | 9,809 |
Accrued expenses and other current liabilities | 24,310 | 23,680 |
Convertible senior notes | 186,143 | 0 |
Current portion of lease liability | 1,588 | 1,545 |
Current portion of acquired contingent consideration | 2,132 | 2,532 |
Deferred revenue | 227 | 384 |
Total current liabilities | 227,773 | 37,950 |
Convertible senior notes | 0 | 167,031 |
Non-current portion of acquired contingent consideration | 27,368 | 38,668 |
Deferred tax liability | 0 | 44,202 |
Non-current portion of lease liability | 3,166 | 4,341 |
Other non-current liabilities | 8,174 | 9,781 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at December 31, 2023 and 2022; no shares issued as of December 31, 2023 and 2022 | ||
Common stock, $0.001 par value per share. Authorized 3,083,333 shares at December 31, 2023 and 2022; issued 1,242,376 and 1,242,376 shares, including those held in treasury, as of December 31, 2023 and 2022, respectively | 1 | 24 |
Treasury stock at cost (278 shares at December 31, 2023 and December 31, 2022) | (638) | (638) |
Additional paid-in capital | 1,030,383 | 1,029,881 |
Accumulated deficit | (1,189,127) | (936,273) |
Accumulated other comprehensive loss | 1,425 | 628 |
Total stockholders' equity (deficit) | (157,956) | 93,622 |
Total liabilities and stockholders’ equity | $ 108,525 | $ 395,595 |
 | Dr. Ron Cohen M.D. |
---|---|
 | acorda.com |
 | Pharmaceuticals |
 | 111 |